These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 39336425)

  • 1. Nanomedicine in Neuroprotection, Neuroregeneration, and Blood-Brain Barrier Modulation: A Narrative Review.
    Krsek A; Jagodic A; Baticic L
    Medicina (Kaunas); 2024 Aug; 60(9):. PubMed ID: 39336425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Targeted nanomedicine in diagnostics and therapy of neurological diseases].
    Bertalan F; László B; Attila V
    Ideggyogy Sz; 2013 May; 66(5-6):155-63. PubMed ID: 23909015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders.
    Sim TM; Tarini D; Dheen ST; Bay BH; Srinivasan DK
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32842530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases.
    Furtado D; Björnmalm M; Ayton S; Bush AI; Kempe K; Caruso F
    Adv Mater; 2018 Nov; 30(46):e1801362. PubMed ID: 30066406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New perspectives on molecular and cellular mechanisms of neuroprotection and neuroregeneration: part II.
    Sharma HS; Sharma A
    Expert Rev Neurother; 2010 Aug; 10(8):1253-7. PubMed ID: 20662749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in nanomaterials for neural applications: opportunities and challenges.
    Sisubalan N; Shalini R; Ramya S; Sivamaruthi BS; Chaiyasut C
    Nanomedicine (Lond); 2023 Nov; 18(26):1979-1994. PubMed ID: 38078433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel nanomaterials for clinical neuroscience.
    Gilmore JL; Yi X; Quan L; Kabanov AV
    J Neuroimmune Pharmacol; 2008 Jun; 3(2):83-94. PubMed ID: 18210200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of chitosan polysaccharides: Neuropharmacological implications and tissue regeneration.
    Ait Hamdan Y; El-Mansoury B; Elouali S; Rachmoune K; Belbachir A; Oudadesse H; Rhazi M
    Int J Biol Macromol; 2024 Nov; 279(Pt 3):135356. PubMed ID: 39244136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood-brain barrier (BBB) to manage neurological disorders.
    Correia AC; Monteiro AR; Silva R; Moreira JN; Sousa Lobo JM; Silva AC
    Adv Drug Deliv Rev; 2022 Oct; 189():114485. PubMed ID: 35970274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Theranostical application of nanomedicine for treating central nervous system disorders.
    Ran W; Xue X
    Sci China Life Sci; 2018 Apr; 61(4):392-399. PubMed ID: 29675554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How Precise are Nanomedicines in Overcoming the Blood-Brain Barrier? A Comprehensive Review of the Literature.
    Mohapatra P; Gopikrishnan M; Doss C GP; Chandrasekaran N
    Int J Nanomedicine; 2024; 19():2441-2467. PubMed ID: 38482521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging.
    Bhaskar S; Tian F; Stoeger T; Kreyling W; de la Fuente JM; Grazú V; Borm P; Estrada G; Ntziachristos V; Razansky D
    Part Fibre Toxicol; 2010 Mar; 7():3. PubMed ID: 20199661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanotheranostics, a future remedy of neurological disorders.
    Sharma M; Dube T; Chibh S; Kour A; Mishra J; Panda JJ
    Expert Opin Drug Deliv; 2019 Feb; 16(2):113-128. PubMed ID: 30572726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harnessing nanomedicine for modulating microglial states in the central nervous system disorders: Challenges and opportunities.
    Li H; Guan M; Zhang NN; Wang Y; Liang T; Wu H; Wang C; Sun T; Liu S
    Biomed Pharmacother; 2024 Aug; 177():117011. PubMed ID: 38917758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomes and nanotechnology in drug development: focus on neurological targets.
    Ramos-Cabrer P; Campos F
    Int J Nanomedicine; 2013; 8():951-60. PubMed ID: 23486739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomedicine based strategies for oligonucleotide traversion across the blood-brain barrier.
    Amulya E; Sikder A; Vambhurkar G; Shah S; Khatri DK; Raghuvanshi RS; Singh SB; Srivastava S
    J Control Release; 2023 Feb; 354():554-571. PubMed ID: 36649742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting specific cells in the brain with nanomedicines for CNS therapies.
    Zhang F; Lin YA; Kannan S; Kannan RM
    J Control Release; 2016 Oct; 240():212-226. PubMed ID: 26686078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
    Khaitan D; Reddy PL; Ningaraj N
    Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Comprehensive Review on Nanomedicine: Promising Approach for Treatment of Brain Tumor through Intranasal Administration.
    Bahadur S; Prakash A
    Curr Drug Targets; 2023; 24(1):71-88. PubMed ID: 36278468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomedicines for the Treatment of CNS Diseases.
    Reynolds JL; Mahato RI
    J Neuroimmune Pharmacol; 2017 Mar; 12(1):1-5. PubMed ID: 28150132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.